Biopharmaceutical company AstraZeneca PLC (STO: AZN; LON: AZN; NYSE: AZN) announced on Tuesday that it has agreed an exclusive worldwide licence with China's Dizal Pharmaceutical Co., Ltd (SSE: 688192) for Zegfrovy (sunvozertinib), an oral irreversible EGFR inhibitor for non-small cell lung cancer (NSCLC).

Zegfrovy is already approved in the US and China for adults with locally advanced or metastatic NSCLC carrying EGFR exon 20 insertion mutations whose disease has progressed after platinum-based chemotherapy. NSCLC accounts for 80–85% of lung cancer cases globally.

Dizal recently reported positive Phase III WU-KONG28 results in first-line NSCLC with exon 20 insertion mutations. Supported by these results, regulatory submissions for first-line use have been filed with the US Food and Drug Administration and China's Center for Drug Evaluation, both of which have granted Breakthrough Therapy Designation.

AstraZeneca will pay Dizal USD600m upfront and up to USD900m in milestone payments, plus tiered royalties on global sales. AstraZeneca will then assume global development and commercialisation responsibilities. The transaction is expected to close in the second half of 2026, subject to customary conditions, and does not affect AstraZeneca's 2026 financial guidance.